ClinicalTrials.gg
Active, not recruitingNCT06386029Updated Nov 5, 2026

The Power Down Pilot Study: A Novel Bedtime Manipulation Protocol

An interventional study of Power Down bedtime manipulation in Autism and Sleep Disturbance, sponsored by University of Pittsburgh. Active, not recruiting at 1 site in United States. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 604 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Planned enrollment
444th of 505
10 · median 44
Started
2025
with 25 others
No phase
296 of 604
83 open now
Primary completion
2026-11
later than 45 of 150 live
Registered
505th of 604
by date

Among the 604 studies in Autistic Disorder with a site in United States, this one is the 444th largest by planned enrollment of the 505 interventional ones that give a count, is one of 26 that started in 2025, is one of 296 with no phase, reaches primary completion later than 45 of the 150 other live ones, and was the 505th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 604 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 604 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot intervention study is to examine the feasibility and acceptability of a novel bedtime manipulation protocol called "The Power Down" for autistic youth, ages 6-10. The main questions it aims to answer are:

  1. Is the Power Down feasible for caregivers to do each night?
  2. Do the families find the Power Down an acceptable intervention to address their child's difficulties settling down to fall asleep?
Read the detailed description

Interested participants will contact the research team and complete screening to determine eligibility (see Screener document). For eligible participants, the informed consent form will be sent and a consent call or video call will be scheduled. The study team will complete the consent process with eligible caregivers (on phone or via video call) and a consent form will be sent via DocuSign for the caregiver to sign.

Following the consent process, questionnaires (below) will be sent via REDCap to complete and a in-lab training meeting will be scheduled. During the in-lab training meeting, the PI (Hartman) will complete the bedtime manipulation training (details found in the Power Down Protocol document found in the Basic Study Information section of this IRB). After the education training, the caregiver(s) will be instructed in the "Power Down massage" and they will practice with their child in the lab and receive feedback on their delivery of the massage. The caregiver(s) and their child will also be given an activity monitor and instructed on the use and care of the device. The caregiver(s) will also review the morning and evening diaries to be completed throughout the study with a study team member.

Following the training session, the caregiver(s) and their child will complete the power down massage nightly, just prior to the time the child would start to try to fall asleep (e.g., after caregiver says "good night", when caregiver leaves the room), for two weeks. They will also complete a morning and evening diary entry, which will be sent virtually. At the end of the two weeks, the activity monitor will be returned to the study team. The participants will connect with the study team to complete an exit interview about their participation in the study and questionnaires about the treatment acceptability.

03

Conditions studied

  • Autism
  • Sleep Disturbance

Browse trials for

Keywords

  • Sleep disturbances
  • Emotion Dysregulation
  • Sensory Processing
04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Child between the ages of 6 and 10 years old (at least 40%, no more than 60% female)
  2. Parent-reported autism diagnosis for child
  3. Parent-reported extended and problematic settling down delay
  4. Parent-reported sensory over-responsivity (a "yes" to at least 8 items in the sensory screening section of the checklist)
  5. Parent willing to participate in nightly routine during the 2 week study
  6. Located within the Pittsburgh area

Exclusion criteria

Exclusion Criteria:

  1. Participants will be excluded if they do not understand English or are unable to travel to University of Pittsburgh Medical Center Western Psychiatric Hospital.
  2. Children who have trauma or other histories for whom physical touch is triggering (per caregiver report) will be excluded.
  3. If a child spends bedtime at a different caregiver's home for >50% of the nights and that caregiver is not willing to participate in this study, the child will be excluded from this study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Power Down pilot arm

    All participants will engage in a 2-week pilot intervention trial with baseline and post-intervention testing.

    Behavioral: Power Down bedtime manipulation

Interventions

  • BehavioralPower Down bedtime manipulation

    The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.

06

What researchers measure

Primary outcomes

  1. Recruitment rates of participants through the trial

    We will use recruitment rates as one of our primary measure of feasibility of this protocol. Benchmark include: Recruitment rates: \>2 caregiver-child dyads enrolled per month

    Time frame: 1 year

  2. Retention rates of participants through the trial

    We will use retention rates as one of our primary measure of feasibility of this protocol. Benchmarks include: Retention rates: \>80% of consented dyads will complete at least 10 nights of the Power Down during the 2 week intervention trial.

    Time frame: 2 weeks

  3. Caregiver reported acceptability

    During the exit interview, caregivers will be asked "Is this intervention an acceptable option for families who are experiencing bedtime difficulties" as a primary measure of acceptability. \>80% of enrolled participants who completed at least 4 days of the Power Down manipulation will report that the intervention is an acceptable option for families like theirs who are experiencing bedtime difficulties (question on post-intervention questions).

    Time frame: Taken at end of 2-week intervention trial

Secondary outcomes

  1. Treatment adherence

    As a secondary measure of feasibility, caregiver reported rates of treatment adherence will be measured. Caregivers will report completing the Power Down massage at least 10/14 nights during the 2 week intervention.

    Time frame: During 2 week trial

  2. Data collection rates- Questionnaires

    We will measure completion rates of questionnaires as a secondary measure of feasibility. Benchmark: \>75% of questionnaires will be completed

    Time frame: At baseline

  3. Data collection rates- Daily diaries

    We will measure completion rates of the number of daily diaries completed as a secondary measure of feasibility. Benchmark: \>75% of daily diaries will be completed

    Time frame: 2 weeks

  4. Data collection rates- Wearing the actigraphy watch

    We will measure the amount of days/nights children wore the actigraphy watch as a secondary measure of feasibility. Benchmarks: Children will tolerate wearing watch for at least 10/14 nights (6+ hours during their reported sleeping times)

    Time frame: 2 weeks

  5. Credibility/Expectancy Questionnaire

    We will gather information about the caregiver's perceived credibility (questions 1-3, Set 1) and expectations (question 4 Set 1, questions 1-2 Set 2) related to the intervention at baseline and at the end of the intervention. Each question is rated on a 9-point scale, with 1 being "do not agree at all" and 9 being "strongly agree). Benchmark: At both baseline and post-intervention, caregivers will rate the intervention an average of 6 (on a 9 point scale) for both credibility and expectations, indicating more than somewhat confident.

    Time frame: 2 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The full study protocol and informed consent forms will be shared with interested researchers upon request. Only aggregate and de-identified data collected throughout the clinical trial will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: Data will be available to share after publication of findings or 2 years after the end of the study, whichever comes first.

Access criteria: Data will be shared with researchers within and outside of the University of Pittsburgh through email requests to the lead principal investigator. The University of Pittsburgh may require a data use agreement be developed and signed by both institutions.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Nov 2026, 15 months.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 15 months is below that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → Nov 2026 and completion Dec 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 26, 2024
StartActual
Jul 5, 2025
Primary completionActual
Nov 1, 2026was Sep 2026
CompletionEst.
May 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Primary completion
Sep 2026→Nov 1, 2026 (actual)
Nov 5, 2026
Study completion
Dec 2026→May 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 2026→Nov 1, 2026 (now actual)
    Study completion Dec 2026→May 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06386029
Responsible party
Amy Hartman, PhD, OTR/L (Assistant Professor, University of Pittsburgh) — Principal investigator
First posted
Apr 26, 2024
Start date
Jul 5, 2025
Primary completion
Nov 1, 2026
Completion
May 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Amy G Hartman, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion